Abstract:Purpose: To review the literature for the safety and efficacy of intralesional 5-fluorouracil (5-FU) in the management of oculofacial scars. Methods: A literature search was performed in July 2019 in the PubMed database to identify reports of the use of 5-FU injections for modulating oculofacial cutaneous scars. The search yielded 152 articles, of which 15 met criteria outlined for assessment. Data were abstracted from these 15 relevant articles. Results: While there were no high-level prospective randomized controlled trials, 8 were lower-quality randomized controlled trial, 3 were retrospective cohort studies, and 4 were case series. Most studies pooled results of facial and nonfacial cutaneous applications. Three studies focused solely on oculofacial applications, and these were all lower-level evidence studies. The study outcomes included scar dimension reduction, erythema, patient satisfaction score, observer assessment of scar improvement, and recurrence rates. 5-Fluorouracil was administered as monotherapy or as part of multimodality treatment with other agents (usually corticosteroids) or with CO2 laser, radiotherapy, or pulsed dye laser. 5-Fluorouracil was usually given as an intralesional injection, but in some studies, it was applied topically after micropuncture of the skin. The number and timing of treatments varied between studies. Overall, the level of safety of 5-FU was high. Pain with injection was the most common reported side effect. Other common adverse side effects included pruritus, telangiectasias, changes in pigmentation, and purpura, and 2 studies noted more serious events, such as ulceration, superficial necrosis, and local infection. There were no severe side effects such as anaphylaxis, immune suppression, secondary malignancy, systemic infection, blindness, or death. In all studies, 5-FU was associated with prophylaxis of oculofacial scars or improvement of keloids or hypertrophic scars in terms of reducing size, erythema, and pruritus. 5-Fluorouracil application was associated with favorable patient satisfaction and observer assessment scores especially compared with corticosteroid injections alone. Conclusions: High-quality randomized controlled trials are currently lacking, and the existing literature is predominately not specific to use of 5-FU on the face. These studies, however, suggest that intralesional 5-FU is safe and probably more effective than other options in the management of cutaneous scars in the oculofacial region. The delivery methods, timing, dosing, and concomitant therapies were highly variable. Further high-quality controlled studies specific to oculofacial scars may be indicated to assess the efficacy of 5-FU and to establish the best protocols for administering this medication.

5-fluorouracil 5% cream for squamous cell carcinoma in situ: Factors impacting treatment response

Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review

Topical 5-Fluorouracil 0.5% as primary treatment for Ocular Surface Squamous Neoplasia

Prognostic Factors for Treatment Failure of Photodynamic Therapy and 5-Fluorouracil in Bowen's Disease

Posttreatment Squamous Cell Carcinoma Antigen in Predicting Treatment Failure for Patients with Cervical Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy

Fluorodeoxyglucose Positron Emission Tomography for Evaluating Early Response During Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

Fluorouracil Supplemented with Oxaliplatin or Irinotecan for Solid Tumors: Indications from Clinical Characteristics and Health Outcomes of Patients

Treatment of Stages I-III Squamous Cell Anal Cancer: A Comparative Effectiveness Systematic Review

Elevated Pretreatment Squamous Cell Carcinoma Antigen Indicates Unfavorable Treatment Outcomes in Cervical Cancer Patients Receiving Definitive Radiotherapy

Analysis of the Efficacy of 5-Fluorouracil in the Treatment of Invasive Moles

Intralesional 5-Fluorouracil for Keloids: A Systematic Review

Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma

5-Fluorouracil Management of Oculofacial Scars: A Systematic Literature Review

Correlation of patient characteristics and tumor histology in patients (pts) with locally advanced cutaneous squamous cell carcinoma (LACSCC) receiving immune checkpoint inhibitor treatment (ICI): A retrospective analysis.

Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma

Topical Application of 5-Fluorouracil for the Treatment of Sinonasal Adenocarcinoma and Inverted Papilloma

149P POSITION: Characterising Risk Factors and Outcomes in Patients (pts) with Stage III Unresectable Non-Small Cell Lung Cancer (unsclc) Who Fail to Complete Concurrent Chemoradiotherapy (ccrt) or Progress During or Shortly after Ccrt

Cell Cycle Perturbation and Acquired 5-Fluorouracil Chemoresistance

Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis, Bowen's Disease, and Squamous Cell Carcinoma: A Systematic Review

Clinical Efficacy of 5-Fluorouracil and Bleomycin in Dermatology

Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma